Abstract 1575P
Background
Exposure to secondhand smoke (SHS) can elevate the overall cancer risk for individuals who have never smoked. Smoke-free policies aim to protect non-smokers from the harmful effects of SHS and align with the guidelines set forth by the World Health Organization (WHO) Framework Convention on Tobacco Control. However, restrictions on smoking in outdoor public places are limited.
Methods
Between 2021 and 2024, the Spanish Association Against Cancer (SAAC) launched a program to enhance smoking prohibitions in outdoor areas. To do so, we first identified public places highly visited by smokers and vulnerable populations. Collaboration agreements were established with city halls, public organizations, and institutions interested in the project. These agreements involved advertising prohibiting smoking and vaping, smoke-free events, and training programs for the personnel responsible for enforcing these recommendations.
Results
Since the program's implementation, 358 collaboration agreements have been signed with 235 city halls through the 52 provinces of Spain. Most agreements (n=129, 36%) were launched to free urban and rural parks and green places from SHS. Other included outdoor sports centers and sports grounds (n=78,22%), universities (n=40,11%), and beaches (n=10, 3%). As a result of the good population and city halls' response to the initiative, the SAAC enforced the inclusion and regulation of outdoor smoke-free places in the new national comprehensive plan for the prevention of smoking.
Conclusions
Population-level initiatives to enforce smoke-free policies in outdoor places can result in new national legislation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Spanish Association Against Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10